• EO Care launches free cannabinoid care platform addressing the lack of clinical guidance for millions of Americans using cannabis for symptom management
• The platform uses a Bayesian AI engine to provide personalised recommendations based on thousands of patient interactions and peer-reviewed research

A new cannabinoid care platform aims to address a growing healthcare paradox: millions of Americans are using medical cannabis for symptom relief, yet most lack access to clinical guidance on safe and effective use.

Boston-based EO Care has launched a free digital health platform designed to provide personalised cannabinoid recommendations to older adults and cancer patients. The move comes as adoption rates climb, with 21% of Americans over 50 and up to 40% of cancer patients now using cannabis regularly for symptom management, while clinical oversight remains scarce.

The clinical guidance gap

The numbers reveal a significant mismatch between usage and medical support. According to data cited by the company, 17% of primary care patients use cannabis regularly for symptom management purposes. 

Yet the healthcare system has been slow to provide structured guidance, leaving patients to navigate product selection, dosing, and potential drug interactions largely on their own.

“For many older adults and people living with chronic conditions, medical cannabinoids offer meaningful symptom management and hope for a better quality of life,” said Sean Collins, CEO and co-founder of EO. “Clinically appropriate, personalised guidance and purpose-designed products are fundamental drivers of safe, effective cannabinoid use.”

The platform was developed and tested in collaboration with patients and clinicians at leading hospitals and NCI-designated cancer centres, suggesting a research-backed approach rather than a purely commercial venture.

How the technology works

At the core of EO’s cannabinoid care platform sits a proprietary adaptive Bayesian care engine—a statistical approach that continuously refines recommendations based on accumulating data. The HIPAA-compliant system draws from multiple sources to generate personalised product, dose, and use recommendations.

The engine considers patient-guided inputs, including symptoms, relevant medical history, current medications, and other care considerations. It cross-references this information against clinical outcomes from thousands of anonymised patient interactions, a library of peer-reviewed studies (both EO-conducted and third-party), a specialised medical cannabinoid ontology, and detailed clinical exclusion rules.

Patients also receive access to ongoing messaging and phone support from EO’s clinician-trained team at no cost.

Business model questions

The platform’s free access model raises questions about sustainability and revenue generation. EO appears to be positioning its own line of hemp-derived Delta-9 THC products as the recommended options within the platform. 

All products are federally legal under current hemp legislation, organic, third-party tested, and produced in GMP-certified facilities, according to the company.

This vertical integration, where the guidance platform recommends the company’s own products, could present potential conflicts of interest; however, the company states that clinical responsibility and personalisation drive its recommendations.

Collins emphasised the broader healthcare implications: “As cannabinoids enter the medical mainstream and patients and providers seek direction and support on their use, EO is committed to providing expert care and optimal products to all who are seeking relief—as well as the cannabinoid efficacy and cost of care impact data that’s so critically needed by all healthcare stakeholders.”

Notable backing & market context

EO’s board and investor roster include prominent healthcare figures. Regina Benjamin, MD, MBA, former Surgeon General of the United States, serves as a board member, alongside Kristi Savacool, former CEO of AON Hewitt, and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. 

Their involvement lends credibility to the venture, though their specific roles in platform development remain unclear. The launch arrives at a pivotal moment for medical cannabis. 

As legalisation expands and social stigma decreases, healthcare providers face increasing pressure to offer guidance on a substance many weren’t trained to discuss. Traditional pharmaceutical approaches to symptom management—particularly for pain, sleep disturbances, and anxiety—have limitations that drive patients toward alternatives.

However, the cannabis market remains fragmented, with product quality varying widely and few standardised approaches to clinical integration. Digital health platforms like EO’s represent one attempt to bridge this gap, though questions remain about long-term efficacy, data privacy, and the appropriate role of commercial entities in clinical guidance.

What this means for healthcare

If successful, platforms like EO’s could establish templates for integrating previously unregulated wellness products into clinical care frameworks. The emphasis on data collection—tracking outcomes across thousands of users—could generate evidence that the field has historically lacked.

For now, the platform represents a bet that personalised, algorithm-driven guidance can improve outcomes for a population already using cannabinoids, often without medical supervision. Whether this approach proves clinically effective and commercially viable remains to be seen.

The platform and products are available at eo.care.

Want to experience the full spectrum of enterprise technology innovation? Join TechEx in Amsterdam, California, and London. Covering AI, Big Data, Cyber Security, IoT, Digital Transformation, Intelligent Automation, Edge Computing, and Data Centres, TechEx brings together global leaders to share real-world use cases and in-depth insights. Click here for more information.

TechHQ is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.